Horizon launches SyntheTx program with H3
CAMBRIDGE, United Kingdom—Horizon Discovery Ltd. and H3 Biomedicine Inc. have come together to launch SyntheTx, a technology partnership program that will aim to supply oncology targets and early-stage drug discovery programs for the pharmaceutical industry. The two companies will screen up to 50 cancer-driving genotypes currently labeled as "undruggable" in hopes of identifying targets that Horizon and H3 Biomedicine can option for further development. Any targets not optioned by the companies will be made available to the industry on commercial terms at the end of the program. Financial terms were not disclosed. The program will target commercialization in the early partnering of putative targets, the partnering of validated targets and partnering of small-molecular lead discovery programs with either in-vitro or in-vivo proof of concept.